Daiichi Sankyo and AstraZeneca Partner with Summit Therapeutics on Cancer Combination Therapy Trials

  • Daiichi Sankyo and AstraZeneca will collaborate with Summit Therapeutics to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types, including lung and breast cancers.
  • The collaboration will begin with a phase 3 trial in first-line triple negative breast cancer (TNBC).
  • Each company will contribute their respective compound for the planned combination trials, with AstraZeneca or Daiichi Sankyo sponsoring the trials.
  • Ivonescimab is a novel, potential first-in-class bispecific antibody combining PD-1 blockade and anti-angiogenesis effects.

This collaboration underscores the growing trend of strategic partnerships in oncology to enhance treatment efficacy through combination therapies. The focus on TNBC and lung cancer highlights the industry's push toward addressing high-unmet medical needs. The involvement of three major players—Daiichi Sankyo, AstraZeneca, and Summit Therapeutics—signals a significant commitment to advancing cancer treatment options.

Clinical Trial Progress
The pace at which the phase 3 trial in first-line TNBC yields results will determine the viability of the Datroway-ivonescimab combination.
Commercialization Strategy
Whether Daiichi Sankyo and AstraZeneca can effectively commercialize the combination therapy while retaining their individual commercial rights.
Pipeline Expansion
How this collaboration impacts Summit Therapeutics' ambition to position ivonescimab as a global PD-1/VEGF partner of choice for novel combinations.